Policy Brief 8, April 2012
Rethinking The R&D Model for Pharmaceutical Products: A Binding Global Convention.
The current incentive-based model of pharmaceutical R&D has failed to make needed medicines available to a large number of people, especially those living in developing countries. This Policy Brief recognizes the urgent need of shifting from the incentive-based model of R&D to a model that effectively promotes not only innovation but more importantly access to medicines, particularly for diseases that disproportionately affect developing countries.
The paper suggests that the negotiation and adoption of an international instrument on pharmaceutical R&D should be a key element for the implementation of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA-PHI) of the WHO. Such an R&D treaty would provide for sustainable funding for R&D which is based on health needs of all populations, especially those in developing countries.
This article was tagged: Affordable Medicines, Health, Intellectual Property, World Health Organization (WHO), World Trade Organization (WTO)